Loading
Altis Labs
Altis Labs makes software that reads the CT scans taken during cancer drug trials and predicts how long patients are likely to live, so that drug makers can tell sooner whether a new treatment is working.
Also called: Altis Labs, Inc.Altis
Overview
Altis Labs, based in Toronto, calls itself an AI endpoint company. Its model IPRO (imaging-based prognostication) generates survival predictions and spatial imaging biomarkers from routine radiology scans; trial imaging is uploaded to its web platform, Nota, for indexing and analysis. The company says IPRO was trained on a multimodal oncology database of imaging, molecular, clinical and outcome data covering over 500,000 patient-years, built with cancer centres. Its published and presented work covers advanced non-small-cell lung cancer, metastatic colorectal cancer and breast cancer, including a Johnson & Johnson post-hoc analysis of the phase 3 MARIPOSA trial presented at the 2026 World Conference on Lung Cancer, which the company says detected a treatment effect before the trial's PFS and overall survival readouts. It announced a collaboration with Johnson & Johnson Innovative Medicine in June 2025. Financing: a $6 million seed round in June 2023 co-led by Benchstrength and Debiopharm Innovation Fund, and a $25 million Series A in September 2026 co-led by OrbiMed and Qiming Venture Partners USA.
Headquarters
Toronto, CA
Funding
All startupsStartup
Investors
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Co-led by OrbiMed and Qiming Venture Partners USA, with Innovation Endeavors, Benchstrength, Fusion Fund and the Cancer Breakthrough Fund. | 2026 | $25M | altislabs.com |
| Seed · Co-led by Benchstrength and Debiopharm Innovation Fund. | 2023 | $6M | altislabs.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- Founding year not stated on the pages read.
- The product is a research tool for trial sponsors, not a test a patient can order.
- Cancers listed are those named in the company's own publication list; the company says the model applies across solid tumours.
Connected
8Similar pages
- CompanyAlterome Therapeutics
Shares OrbiMed, Breast cancer (all types), Colorectal cancer, Non-small-cell lung cancer.
- CompanyConcr
Shares Digital twins and virtual control arms, Breast cancer (all types).
- CompanyQuibim
Shares Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC), Breast cancer (all types).
- CompanySidewinder Therapeutics
Shares OrbiMed, Colorectal cancer, Non-small-cell lung cancer.
- CompanyBlossomHill Therapeutics
Shares OrbiMed, Colorectal cancer.
- TechnologyCT body composition and sarcopenia measurement
Shares Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC), Colorectal cancer, Non-small-cell lung cancer.
- TechnologyFES PET (oestrogen receptor imaging)
Shares Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC), Breast cancer (all types).
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
altislabs.com · 4
orbimed.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/